Jazz Pharmaceuticals plc — Director's Dealing 2023

Dec 6, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2023-12-04

Reporting Person: Smith Mark Douglas (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-12-04	Ordinary Shares	S	417	$119.27	Disposed	6888	Direct

Footnotes

F1: Shares sold to satisfy tax obligations arising out of the vesting of previously granted restricted stock units.